Abstract OBJECTIVE: To study the efficacy of erythropoietinin (EPO) in the treatment of moderate or severe hypoxic-ischemic encephalopathy (HIE) in neonates. METHODS: Seventy neonates with moderate or severe HIE were randomly assigned to two groups: EPO treatment and control (n=35 each). The EPO treatment group included 22 cases of moderate HIE and 13 cases of severe HIE. The control group included 24 cases of moderate HIE and 11 cases of severe HIE. Thirty-five healthy full-term infants served as normal group. The control group received a conventional treatment. Beside the conventional treatment, the EPO treatment group was intravenously injected with EPO of 200 IU/kg?d, 3 times weekly. Routine blood test was performed every 6 days. EPO dose was adjusted based on the results of the routine blood test. The course of EPO treatment was 2 to 4 weeks. Neonatal Behavioral Neurological Assessment (NBNA) was performed at age of 28 days. The infant development test of Child Development Centre of China (CDCC) was performed at ages of 3 months and 6 months. RESULTS: The percentage of normal NBNA scores in the EPO treatment group was significantly higher than that in the control group at age of 28 days (P<0.05), but was significantly lower than that in the normal group (P<0.01). The CDCC test including physical development index (PDI) and physical development index (MDI) showed the percentage of normal results in the EPO treatment group was significantly higher than in the control group at age of 3 months (P<0.05), but was significantly lower than in the normal group (P<0.01). The CDCC test including PDI and MDI showed that the percentage of normal results in the EPO treatment group was significantly higher than in the control group at age of 6 months. The MDI test results in the EPO treatment group were not significantly different from those in the normal group at age of 6 months, but the percentage of normal results in the PDI test in the EPO treatment group was still significantly lower than that in the normal group (P<0.05). CONCLUSIONS: EPO treatment has neuroprotective effects against moderate or severe HIE and improves longterm behavioral neurological developments in neonates.
WANG Ying-Juan,PAN Kai-Li,ZHAO Xiao-Li et al. Therapeutic effects of erythropoietin on hypoxic-ischemic encephalopathy in neonates[J]. 中国当代儿科杂志, 2011, 13(11): 855-858.
WANG Ying-Juan,PAN Kai-Li,ZHAO Xiao-Li et al. Therapeutic effects of erythropoietin on hypoxic-ischemic encephalopathy in neonates[J]. CJCP, 2011, 13(11): 855-858.
［7］Sobh MA, el-Tantawy AE, Said E, Atta MG, Refaie A, Nagati M, et al. Effect of treatment of anaemia with erythropoietin on neuromuscular function in patients on long-term haemodialysis［J］. Scand J Urol Nephrol, 1992, 26(3): 65-69.
［8］Spandou E, Papoutsopoulou S, Soubasi V, Karkavelas G, Simeonidou C, Kremenopoulos G, et al. Hypoxia-ischemia affects erythropoietin and erythropoietin receptor expression pattern in the neonatal rat brain［J］.Brain Res, 2004, 1021(2): 167-172.
［10］Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin［J］. Biochim Biophys Acta, 2007, 1776(1): 1-9.
［11］Tao WY, Wen F, Zhang H, Liua G. The signal transduction mediated by erythropoietin and proinflammatory cytokines in the JAK/STAT pathway in the children with cerebral palsy［J］. Brain Dev, 2009, 31(3): 200-207.
［12］Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation［J］. Mol Cell Biol, 1992, 12(12): 5447-5454.
［13］Martínez-Estrada OM, Rodríguez-Mill-n E, Gonz-lez-De Vicente E, Reina M. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability［J］. Eur J Neurosci, 2003, 18(9): 2538-2544.
［14］Mainie P. Is there a role for erythropoietin in neonatal medicine?［J］. Early Hum Dev, 2008, 84(8): 525-532.
［15］Fu ZQ, Shao QL, Shen JL, Zhang YJ, Zhao XX, Yao L. Effect of carbamylated erythropoietin major histocompatibility complex expression and neural differentiation of human neural stem cells［J］. J Neuroimmunol, 2010, 221(1-2): 15-24.
［16］Juul SE, McPherson RJ. Recent trends in erythropoietin-mediated neuroprotection［J］. Int J Dev Neurosci, 2008, 26(1): 103-111.
［17］Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse［J］. Mol Pharm, 2010, 7(6): 2148-2155.
